ProCE Banner Activity

A Global Perspective: An Expert Roundtable on PARP Inhibitors in the Treatment of Metastatic Breast Cancer

Watch this panel of international experts discuss how they are using PARP inhibitors in the management of their patients metastatic breast cancer

Released: November 24, 2020

Expiration: November 23, 2021

No longer available for credit.

Share

Faculty

Pierfranco Conte

Pierfranco Conte, MD

Professor
DiSCOG
University of Padua
Padua, Italy
Director
U.O.C. Oncology 2
Istituto Oncologico Veneto, IOV - IRCSS
Padova, Italy

Véronique Diéras

Véronique Diéras, MD

Head, Breast Group
Medical Oncology Department
Centre Eugene Marquis UNICANCER
Rennes, France

Mark E. Robson

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating metastatic breast cancer
  • Identify patients with metastatic breast cancer based on genetic testing and previous therapy that are most likely to benefit from treatment with PARP inhibitors
  • Integrate single-agent PARP inhibitors into the treatment of appropriately selected patients with metastatic breast cancer
  • Refer eligible patients with metastatic breast cancer to clinical trials of single-agent PARP inhibitors and combinations with other anticancer therapies

Faculty Disclosure

Primary Author

Pierfranco Conte, MD

Professor
DiSCOG
University of Padua
Padua, Italy
Director
U.O.C. Oncology 2
Istituto Oncologico Veneto, IOV - IRCSS
Padova, Italy

Pierfranco Conte, MD, PhD, has discosed that he has received consulting fees from AstraZeneca, BristolMyersSquibb, Eli Lilly, Merck, and Roche, as well as fees for non-CME services from AstraZeneca, Merck, and Roche.

Véronique Diéras, MD

Head, Breast Group
Medical Oncology Department
Centre Eugene Marquis UNICANCER
Rennes, France

Véronique Diéras, MD, has disclosed that she has received consulting fees from Abbvie, AstraZeneca, MSD, and Pfizer.

Mark E. Robson, MD

Chief, Breast Medicine Service
Attending Physician
Clinical Genetics and Breast Medicine Services
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Mark E. Robson, MD, has disclosed that he has received consulting fees from AstraZeneca and Pfizer.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.